Clay B Siegal is the Chief Executive Officer as well as the President of Seattle Genetics. He is also the President of the Board at Seattle Genetics. In fact, Clay Siegall is one of the founders of this company. This company was founded in 1998.
Clay Siegall is a qualified scientist. His company is based on scientific innovations. There is an innate desire over here to assist patients. He is a great leader. He has the ability to manage the organization well enough. Currently his company is developing an antibody-drug conjugate. This will help to treat cancer.
He is well aware that he cannot do it all alone. This is why he has entered into some strategic partnerships with pharma companies that include Roche, Pfizer, in addition to AbbVie, and GlaxoSmithKline.
Clay Siegall is doing a number of money-raising activities in order to finance his research. This way he has been able to secure millions of dollars. This has been managed through public as well as private financing.
It was in 2001 that the Initial Public Offer came out.
- Siegall joined Ultragenyx in 2014 and became a member of that board. He is the co-founder of Seattle Genetics. Prior to this, Dr. Siegall was serving with the Bristol-Myers Squibb Pharmaceutical Research Institute. He worked there between1991 and 1997.
Clay Siegall has worked for the National Cancer Institute. He was with the National Institute of Health. This was between 1988 and 1991. He is the member of the board of directors of two private companies that are working in the field of biotechnology. These are Mirna Therapeutics as well as BioPharmaceuticals.
Clay Siegall holds a B.S degree in Zoology from the University of Maryland. He has earned his doctorate in Genetics from the George Washington University.
In 2013, Clay Siegall was appointed to the Board of Directors at Mirna Therapeutics. This was because Mirna was looking for someone with a lot of experience in the pharmaceutical industry. They wanted someone who could help Mirna as they developed the microRNA-based therapeutics.
As per Clay Siegall, microRNA-based therapeutics is an upcoming field in cancer research.